Skip to main content

ESMO Highlights

Meeting Highlights
ESMO Highlights
Oregovomab and Nivolumab as a Combinatorial Immunotherapy Strategy for Recurrent Epithelial Ovarian Cancer
Read More
Meeting Highlights
ESMO Highlights
Maintenance Olaparib Following Platinum-Based Chemotherapy in Newly Diagnosed Patients with Advanced Ovarian Cancer and a BRCA1/2 Mutation: Results from the Phase 3 SOLO1 Trial
Read More
Meeting Highlights
ESMO Highlights
A Phase 2 Trial of Combination Nivolumab and Bevacizumab in Recurrent Ovarian Cancer
Read More
Meeting Highlights
ESMO Highlights
Association of PD-L1 Expression with Clinical Response to Pembrolizumab in Patients with Advanced Recurrent Ovarian Cancer
Read More
Meeting Highlights
ESMO Highlights
A Phase 1/2 Study of Chemo-Immunotherapy with Durvalumab and Pegylated Liposomal Doxorubicin (PLD) in Platinum-Resistant Recurrent Ovarian Cancer
Read More
Meeting Highlights
ESMO Highlights
Meta-Analysis of PARP-Inhibitor–Associated Gastrointestinal and Hepatic Toxicities
Read More
Meeting Highlights
ESMO Highlights
Clinical Characteristics of Ovarian Cancer Relapse in BRCA1/2 Germ-Line Mutation Carriers and Noncarriers
Read More
Meeting Highlights
ESMO Highlights
A Phase 2 Study of Durvalumab, a PD-L1 Inhibitor, and Olaparib in Recurrent Ovarian Cancer
Read More
Meeting Highlights
ESMO Highlights
Olaparib Maintenance Therapy in Patients with Platinum-Sensitive Relapsed Ovarian Cancer and Stable Disease
Read More
Meeting Highlights
ESMO Highlights
Long-Term Tolerability of Olaparib Tablets as Maintenance Therapy for Platinum-Sensitive Relapsed Ovarian Cancer
Read More
Page 4 of 5
Results 31 - 40 of 44